The leadership team at Corium brings together industry-leading experts in drug development, manufacturing, and commercialization who are dedicated to doing more for our partners and patients.
Dr. Kornowski has been a Senior Partner at Gurnet Point Capital since 2018. Prior to joining Gurnet Point Capital, she was Executive Vice-President of Roche Partnering. In that role she focused on establishing external partnerships with biotechnology and research institutions worldwide for Roche Holding AG, one of the world's largest healthcare companies. She was also a member of Roche's Extended Global Executive Committee.
Dr. Kornowski and her team completed over 50 deals per year in her role as head of partnering at Roche. Previously, she led Roche's major affiliate for 5 years in France. Dr. Kornowski also spent 11 years in various leadership roles at Merck in the United States, France, and Israel. She spent the early years of her career at Abbott and Sanofi, in France and the United States. Dr. Kornowski has an M.B.A. from the University of Chicago Booth and a Ph.D. in Pharmacy from Paris Descartes University.
Mr. Moore joined Gurnet Point Capital in early 2020. Prior to joining Gurnet Point, he was the Chief Executive Officer of one of the infectious disease businesses of Roivant Sciences, a biopharmaceutical drug development company. Before his role at Roivant, Mr. Moore was Senior Vice President, Commercial, at Novo Nordisk U.S., where he led the successful transformation of the company's commercial operating model into a purely integrated sales and marketing organization. He guided the company through multiple new product launches, including one of the most successful launches in type 2 diabetes to date.
Mr. Moore began his career at Ortho-McNeil, a Johnson & Johnson company, as a sales representative, progressing through key commercial management roles including market access, sales leadership, marketing, and new product development in a wide variety of therapeutic areas. He later was named Group Marketing Director at Janssen Pharmaceuticals, another Johnson & Johnson business, before making the transition to biotech and taking the position of VP Global Commercial Operations and later Chief Business Officer at Tranzyme Pharma. At Tranzyme, Mr. Moore successfully drove the pre-launch of the company's primary asset. In 2013, he was named Chief Commercial Officer and later President of Cempra Pharmaceuticals, a biotech company, where he transformed the organization from development stage to commercial ready.
In addition to Corium, Mr. Moore serves as a director and board member of several pharmaceutical companies, including Alladapt Immunotherapeutics, Inc., Auregen BioTherapeutics Inc., Boston Pharmaceuticals Inc., Innocoll Holdings plc and Tremeau Pharmaceuticals, Inc.
Perry Sternberg, CEO of Corium Inc, delivers a vision of a healthcare company that is patients' and caregivers' partner of choice. Based on an ethos of community and compassion, Corium strives to make a difference in the lives of others. As CEO, Perry focuses the company's efforts on the empowerment of patients, caregivers, and its employees.
According to Perry, every existing and potential relationship relies on the organic building of good communication and trust, not one-sided messaging. Leading a healthcare business means being approachable, treating others with respect, and being open and eager to hear others' ideas. As Perry says, “Every person has something valuable and important to bring to the table when it comes to improving patient and caregiver outcomes.”
In his 25 years of experience in biotechnology and pharmaceuticals, Perry has overseen the launches of more than 20 products across a wide range of therapeutic areas in diverse markets. Under his leadership, Corium has filed and submitted for FDA approval of a prescription treatment for Alzheimer's disease. The company has also continued its strategic partnerships to bring to market an ADHD treatment, and produce contraception and in-demand oral care products. Perry is passionate about, and thrilled by, the future that Corium is building for the people the company seeks to serve.
Perry spends his downtime with his wife, 3 children, and their family dog, and enjoys travel.
Mr. Wilson is a partner at Gurnet Point Capital. Prior to joining Gurnet Point Capital, Mr. Wilson was President and CEO at Stealth BioTherapeutics, a late-stage clinical biotechnology company developing technologies to treat mitochondrial dysfunction in common and rare diseases.
Mr. Wilson has extensive experience in biotechnology and venture investing, leading transactions from seed-investments to near commercial assets. For more than a decade, he was a member of the life science investment team at the Morningside Group, a privately held investment firm. With Morningside, he assisted with multiple financings, including several public and private companies such as Chimerix (NASDAQ: CMRX), Genocea (NASDAQ: GNCA), BioVex (acquired by Amgen), Aduro (NASDAQ: ADRO), and Argos (NASDAQ: ARGS).
Mr. Wilson also served as a director and board member for nonclinical and clinical stage companies, providing operational and management support to a portfolio of companies developing drugs across a broad spectrum of therapeutic focus, including orphan diseases, cardio-renal disorders, oncology, cell-therapy, and ophthalmology. He has lectured extensively on life science investing and management, and is a long-time supporter of patient-advocacy groups. Mr. Wilson holds a law degree and a chemical engineering degree, both from the University of Wisconsin.